Argus expects United Therapeutics to reach its 2012 sales target, and the firm thinks the stock's current price undervalues the company's new products and pipeline. The firm raised its target on the shares to $60 from $52 and maintains a Buy rating.
Happy demi-anniversary, stock market rally. Will the honeymoon ever end?